18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma - PubMed (original) (raw)
18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma
Masahiro Kikuchi et al. Ann Nucl Med. 2011 Nov.
Abstract
Objective: To evaluate the usefulness of [(18)F]fluoromisonidazole ([(18)F]FMISO)-positron emission tomography (PET) prior to the treatment of head and neck squamous cell carcinoma.
Methods: Seventeen patients with untreated HNSCC underwent pretreatment [(18)F]FMISO PET. Six of them underwent definitive surgery and the remaining 11 definitive (chemo-)radiotherapy. We evaluated 30 lesions from the 17 patients. SUVmax and tumor-to-muscle ratios (TMR) were measured as hypoxia indicators. Tumors equal to or above the median value were defined as tumor with high uptake of [(18)F]FMISO and those below as tumor with low uptake of [(18)F]FMISO in both indicators. Local control rates with radiotherapy, event-free survival and disease-specific survival (DSS) rates with radiotherapy or operation were compared.
Result: [(18)F]FMISO-PET imaging of 30 lesions resulted in a SUVmax median value of 2.3 and a TMR median value of 1.3. Local control rates with radiotherapy (20-month median follow-up duration) were significantly lower in the tumor group with high uptake of [(18)F]FMISO compared to the tumor group with low uptake of [(18)F]FMISO using either SUVmax or TMR as the hypoxic indicator (P = 0.02 and 0.04, respectively). DSS rate with radiotherapy or operation (21-month median follow-up duration) was significantly lower in the patient group with high uptake of [(18)F]FMISO compared to the patient group with low uptake of [(18)F]FMISO defined by SUVmax (P = 0.04), but was not by TMR (P = 0.57).
Conclusions: Radiotherapy outcome and survival prognosis (radiotherapy or operation) in HNSCC may be predicted by carrying out [(18)F]FMISO PET before treatment.
Similar articles
- High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, Kuge Y, Shirato H, Tamaki N. Okamoto S, et al. J Nucl Med. 2013 Feb;54(2):201-7. doi: 10.2967/jnumed.112.109330. Epub 2013 Jan 15. J Nucl Med. 2013. PMID: 23321456 - Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Schütze C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Zips D, Hessel F, Krause M, Thames H, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B. Schütze C, et al. Radiother Oncol. 2014 Apr;111(1):81-7. doi: 10.1016/j.radonc.2014.02.005. Epub 2014 Mar 14. Radiother Oncol. 2014. PMID: 24636842 - The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S, Shiga T, Yasuda K, Watanabe S, Hirata K, Nishijima KI, Magota K, Kasai K, Onimaru R, Tuchiya K, Kuge Y, Shirato H, Tamaki N. Okamoto S, et al. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2147-2154. doi: 10.1007/s00259-016-3431-4. Epub 2016 Jun 1. Eur J Nucl Med Mol Imaging. 2016. PMID: 27251644 Clinical Trial. - Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer.
Hodolič M, Fettich J, Kairemo K. Hodolič M, et al. Curr Radiopharm. 2015;8(1):32-7. doi: 10.2174/1874471008666150316222400. Curr Radiopharm. 2015. PMID: 25808959 Review. - [Metabolic tailoring in radiotherapy for head and neck cancer].
Servagi-Vernat S, Giraud P. Servagi-Vernat S, et al. Cancer Radiother. 2014 Oct;18(5-6):565-71. doi: 10.1016/j.canrad.2014.05.011. Epub 2014 Aug 30. Cancer Radiother. 2014. PMID: 25179254 Review. French.
Cited by
- Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer.
Lazzeroni M, Ureba A, Wiedenmann N, Nicolay NH, Mix M, Thomann B, Baltas D, Toma-Dasu I, Grosu AL. Lazzeroni M, et al. Phys Imaging Radiat Oncol. 2021 Feb 11;17:100-105. doi: 10.1016/j.phro.2021.01.011. eCollection 2021 Jan. Phys Imaging Radiat Oncol. 2021. PMID: 33898787 Free PMC article. - Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET.
Huang Y, Fan J, Li Y, Fu S, Chen Y, Wu J. Huang Y, et al. Front Oncol. 2021 Sep 7;11:731503. doi: 10.3389/fonc.2021.731503. eCollection 2021. Front Oncol. 2021. PMID: 34557414 Free PMC article. Review. - Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.
Kelada OJ, Rockwell S, Zheng MQ, Huang Y, Liu Y, Booth CJ, Decker RH, Oelfke U, Carson RE, Carlson DJ. Kelada OJ, et al. Mol Imaging Biol. 2017 Dec;19(6):893-902. doi: 10.1007/s11307-017-1083-9. Mol Imaging Biol. 2017. PMID: 28409339 Free PMC article. - The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.
Araos J, Sleeman JP, Garvalov BK. Araos J, et al. Clin Exp Metastasis. 2018 Oct;35(7):563-599. doi: 10.1007/s10585-018-9930-x. Epub 2018 Aug 31. Clin Exp Metastasis. 2018. PMID: 30171389 Review. - Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer.
Asano A, Ueda S, Kuji I, Yamane T, Takeuchi H, Hirokawa E, Sugitani I, Shimada H, Hasebe T, Osaki A, Saeki T. Asano A, et al. Breast Cancer Res. 2018 Jul 27;20(1):78. doi: 10.1186/s13058-018-0970-6. Breast Cancer Res. 2018. PMID: 30053906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical